Actively Recruiting

Phase Not Applicable
Age: 5Years - 17Years
All Genders
ID06135311

Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation (TENS) for Treating Nocturnal Enuresis in Children

Led by Albany Medical College · Updated on 2025-10-02

70

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research investigates the use of Transcutaneous Electrical Nerve Stimulation (TENS) therapy to treat primary nocturnal enuresis (bedwetting) in children aged 5 to 17 years. Children referred to a pediatric urology clinic who have not improved after behavioral modifications will be offered either a bedwetting alarm or TENS therapy. The study aims to compare two different pulse widths of TENS to understand their effects on nighttime wetting episodes and bladder symptoms. Participants will be randomly assigned to one of two groups: one receiving TENS with a high pulse width of 260 microseconds and the other with a low pulse width of 50 microseconds. Each child will use the TENS unit with electrodes placed on the medial ankle along the posterior tibial nerve for 30 minutes at bedtime every night for 30 days. Intensity will be set based on the child's sensitivity, and families will be instructed on device use. There is no placebo group; all participants receive active treatment. During the study, parents and children will keep nightly diaries tracking the frequency and severity of bedwetting using a wet sheet scale. Before and after treatment, they will complete the Bowel & Bladder Questionnaire to assess bladder symptoms. Follow-up visits will occur after one month to evaluate progress and any side effects. The main outcome measured is the percentage of wet nights over 30 days, alongside severity and symptom questionnaire results. Participation includes daily monitoring and a month of treatment.

CONDITIONS

Brief Title

Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children

Who Can Participate

Age: 5Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Presenting with nocturnal enuresis occurring more than once a week
  • Failed behavioral modification treatment in the 30 days prior to randomization
  • Ability to provide informed consent and assent and complete study requirements
Not Eligible

You will not qualify if you...

  • Use of pharmacologic treatment or alternative therapy for nocturnal enuresis or urologic disorders within the past 30 days
  • Presence of daytime urinary incontinence symptoms
  • Known "high volume" voiders based on history
  • Bedwetting episodes less than twice per week on average
  • Taking medications that predispose to incontinence (e.g., Lithium for bipolar disorder)
  • Other voiding or neurologic disorders such as overactive bladder or myelomeningocele
  • Secondary causes for nocturnal enuresis like cystitis or obstructive sleep apnea
  • Contraindications to TENS use including pacemakers, lymphedema, pregnancy, malignancy, bleeding or clotting disorders, unhealthy tissue, seizure disorders, or impaired cognition
  • History of heart disease or related complications

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 30 days

Participants use a transcutaneous electrical nerve stimulation (TENS) unit nightly at bedtime for 30 minutes, with pulse width set according to their group assignment to treat nocturnal enuresis. They and their caretakers will record nightly voiding diaries during this period.

1 baseline visit and 1 follow-up visit

Trial Site Locations

Total: 1 location

1

Albany Medical College

Albany, New York, United States, 12208

Actively Recruiting

Loading map...

Research Team

B

Brenda Romeo, CCRC

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Transcutaneous electrical neural stimulation for the treatment of urinary urgency or urge-incontinence in children and adolescents: a Phase II clinica.

Amanda Carolina Almeida de Alcantara, Maria Júlia Gonçalves de Mello, Eduardo Just da Costa e Silva...

https://pubmed.ncbi.nlm.nih.gov/26398655

Nonpharmacological treatment of lower urinary tract dysfunction using biofeedback and transcutaneous electrical stimulation: a pilot study.

Ubirajara Barroso, Patrícia Lordêlo, Antônio A Lopes...

https://pubmed.ncbi.nlm.nih.gov/16831163

Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.

Ubirajara Barroso, Walter Viterbo, Joana Bittencourt...

https://pubmed.ncbi.nlm.nih.gov/23422257

Development and Validation of Symptom Score for Total Bladder-Bowel Dysfunction: Subscales for Overactive Bladder and Dysfunctional Voiding.

U Sillén, S Sjöström, M Doroszkiewicz...

https://pubmed.ncbi.nlm.nih.gov/32469626

Electrical stimulation of somatic afferent nerves in the foot increases bladder capacity in healthy human subjects.

Mang L Chen, Christopher J Chermansky, Bing Shen...

https://pubmed.ncbi.nlm.nih.gov/24113017

[Transcutaneous electrical acupoint stimulation combined with auricular acupoint sticking for treatment of primary nocturnal enuresis].

Yong-Jun Chen, Guo-Ying Zhou, Jian-Hong Jin

https://pubmed.ncbi.nlm.nih.gov/20518171

Treatment of non-monosymptomatic nocturnal enuresis by transcutaneous parasacral electrical nerve stimulation.

Patrícia Lordêlo, Igor Benevides, Eric Goodwin Kerner...

https://pubmed.ncbi.nlm.nih.gov/20837326